Visalytics
Visalytics
approved EB-2 (NIW)

Institute Senior Research Scientist

Pharmaceutical Sciences · China · 2024-02-21

Processing Time
7 days
Decision Date
2024-02-21
Location
Texas
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to continue her research in pharmaceutical sciences, specifically focusing on advancing cancer therapy through the development of polymeric drugs. Her work involves sophisticated investigations into novel drug delivery systems designed to increase treatment efficacy while reducing toxicity for conditions like cancer and Inflammatory Bowel Disease (IBD).

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The research addresses critical public health issues like cancer and IBD, which are of strategic significance to the U.S. biomedical sector.

2 Well-positioned to Advance the Endeavor Met

The petitioner's PhD, 26 publications, and 1,191 citations demonstrate her status as an authority in the field.

3 Waiver of Job Offer and Labor Certification Met

On balance, the petitioner's unique expertise and the potential for her work to improve patient outcomes and quality of life for millions of Americans benefit the U.S. significantly.

Why This Petition Was Approved

The petition was approved based on the petitioner's PhD in pharmaceutical sciences and a strong record of 26 peer-reviewed journal articles and one book chapter. Her work garnered 1,191 citations and she demonstrated her expertise by performing 12 peer reviews for professional journals. The case was supported by four recommendation letters from international experts and evidence of funding from the NIH and NSF.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Reference Letters Independent
Grants
Judging Experience
Original Contributions
Government Alignment

Similar Cases

Postdoctoral Researcher

Pharmaceuticals · Bangladesh

WeGreened EB-2 (NIW) approved
Illinois 535 days 2026-01-16
The petitioner proposes to continue research in clinical pharmaceutical sciences, specifically focusing on understanding cancer development at the molecular level. The work involves investigating mechanisms such as genome instability and replication stress to identify actionable molecular targets for cost-conscious therapeutic strategies.
View Case

Others

Pharmaceuticals · South Korea

WeGreened EB-2 (NIW) approved
54 days 2025-03-24
The petitioner proposes to continue her research in pharmaceutical science by integrating advanced technologies and computational approaches to develop novel drug candidates. Her work focuses on improving drug delivery systems to create more effective, affordable, and stable medications for chronic diseases including cancer, diabetes, hypertension, and neurodegenerative diseases.
View Case

Research Scientist

Pharmaceuticals · China

WeGreened EB-2 (NIW) approved
Texas 296 days 2026-01-14
The petitioner proposes to advance pharmacological research by improving drug-conjugate therapies to create more selective delivery vehicles for cancer treatment. This work focuses on engineering therapeutic payloads to concentrate in tumor cells while limiting exposure to healthy tissue, thereby reducing off-target effects and collateral damage.
View Case

Postdoctoral Researcher

Biotechnology · China

WeGreened EB-2 (NIW) approved
New York 169 days 2025-04-09
The petitioner proposes to continue research in the development of pharmacokinetics (PK) and pharmacodynamics (PD) studies, specifically focusing on the targeted delivery of anti-tumor and antimicrobial medications. This work involves synthesizing bioactive polymers, spatial metabolomics, and protein engineering to improve therapeutic efficacy. The endeavor aims to advance precision medications that reduce side effects for challenging diseases.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Pharmaceuticals cases More cases from China

Case data sourced from publicly available petition decisions and case studies. Decision date: 2024-02-21.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 7 days
Criteria Met 3 / 3
Evidence Types 7

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,895
Success Rate 54.2%
Sustained 2,112
Dismissed 1,687

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in China All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist